Paramount's bid to acquire Warner Bros. Discovery has cleared a major regulatory hurdle, but the deal's future in Hollywood now hinges on a promise that goes to the heart of the movie business: how many films will actually reach theaters, and how consistently they will do so.
Under a settlement reached this week with a group of state attorneys general over antitrust concerns, Paramount CEO David Ellison agreed that the newly combined company will release at least 30 films into theaters in 2027 and 2028, and at least 32 films in each of the following three years, 2029 through 2031. The commitment is designed to reassure regulators, theater owners and industry stakeholders that the merger will not shrink the theatrical pipeline at a time when Hollywood is still recovering from the pandemic-era collapse in production and attendance.
Ellison has framed the pledge as a meaningful boost for cinemas. He has been touting the theatrical commitment since as early as April, when he discussed it at CinemaCon, the industry's annual convention. The pitch appears to have helped win over the CEOs of the "Big Three" cinema chains — AMC's Adam Aron, Cinemark's Sean Gamble and Regal's Eduardo Acuna — even before the settlement with the states was finalized.
Cinema United, the lobbying group representing theater owners, had been firmly opposed to the merger, but this week it gave the agreement its approval, saying the deal with the states "accomplishes many of exhibition's objectives." For a sector that has spent years warning about the erosion of theatrical exclusivity and the shrinking number of studio releases, the promise of a steady slate from a larger studio is being treated by some as a rare concession.
Still, the applause is far from universal.
Several theater executives, speaking anonymously to CNBC so they could be candid, said they remain unconvinced that the promise will translate into the kind of robust, varied movie slate that exhibitors need. Their concern is not simply about the number of titles, but about what kind of titles those will be, how many will be wide releases, and whether the company will actually deliver enough films with the scale and marketing muscle to drive audiences into cinemas.
Paul Dergarabedian, head of marketplace trends at Rentrak, said the headline number alone does not settle the question.
"This is much more complicated than simply asking whether 30 movies is enough," Dergarabedian told CNBC. "Thirty wide releases would represent a meaningful commitment to theatrical, and I think everyone in exhibition would welcome a robust pipeline of films.
"But ultimately the proof will be in how those movies perform, how varied the slate is, how consistently they reach theaters and how the combined company executes on those commitments," he said.
That skepticism reflects a broader anxiety in the exhibition business. Consolidation among major studios has historically meant fewer films in circulation, which can squeeze revenue for smaller theater chains and independent operators that depend on a steady flow of new titles. Larger chains with hundreds of locations can better absorb volatility, but smaller operators have less leverage when negotiating windowing terms, rental fees and access to premium content.
Those concerns have sharpened as the industry's economics have changed dramatically since Covid shuttered theaters and disrupted production pipelines. Fewer screens and fewer moviegoers have forced operators to adapt, even as higher ticket prices have helped cushion the blow. Domestic box office is expected to top $10 billion for the first time since the pandemic, but that milestone masks a business still searching for a stable post-Covid footing.
The settlement also includes specific requirements on how many theatrical releases the company must distribute over the next five years, how many of those must be wide releases, and how many must carry budgets above $50 million. Paramount has agreed to steep penalties if it fails to meet those thresholds, a sign that regulators wanted more than a vague promise of support for theaters.
Even so, some in the exhibition community worry about what happens when the five-year agreement ends. Several theater owners told CNBC they fear Paramount may not be able to sustain 30-plus theatrical releases once the settlement obligations expire, especially if the merged company decides to prioritize streaming, franchise concentration or other corporate goals over a broad theatrical slate.
That uncertainty may prove to be the most important issue of all. For now, the merger's defenders can point to a concrete commitment and a larger studio footprint that could, in theory, deliver more films to more screens. But the skeptics argue that Hollywood has heard promises before, and that the real test will come not in the announcement itself, but in the years of release calendars, box office results and bargaining fights that follow.
In an industry still rebuilding its audience and its supply chain, Paramount's promise is being read as both a reassurance and a warning: more movies may be coming, but whether they are enough — and whether they last — remains an open question.